AMARIN CORP PLC\UK Weighted Average Number of Shares Outstanding, Basic and Diluted
AMARIN CORP PLC\UK (AMRN) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 397.81 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-04
- AMARIN CORP PLC\UK weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 397.81M shares, a 0.80% increase year-over-year.
- AMARIN CORP PLC\UK weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 396.62K shares, a 1.78% increase year-over-year.
- AMARIN CORP PLC\UK weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 394.64M shares, a 9.28% increase year-over-year.
- AMARIN CORP PLC\UK weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 1.53B shares, a 324.64% increase year-over-year.
- AMARIN CORP PLC\UK weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 381.76M shares, a 11.45% increase from fiscal 2019.
- AMARIN CORP PLC\UK weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 342.54M shares, a 15.24% increase from fiscal 2018.
- AMARIN CORP PLC\UK weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 297.24M shares, a 9.82% increase from fiscal 2017.
- AMARIN CORP PLC\UK weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 270.65M shares, a 27.74% increase from fiscal 2016.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|---|---|
| 2022-03-31 | 397.81M shares 10-Q · filed 2022-05-04 | |||||
| 2021-09-30 | 396.62K shares 10-Q · filed 2021-11-03 | 395.68K shares 10-Q · filed 2021-11-03 | ||||
| 2021-03-31 | 394.64M shares 10-Q · filed 2022-05-04 | 960.27M shares derived: average of 2 quarters · filed 2022-05-04 | 640.31M shares derived: average of 3 quarters · filed 2022-05-04 | |||
| 2020-12-31 | 1.53B shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 763.14M shares derived: average of 2 quarters · filed 2021-11-03 | 381.76M shares 10-K · filed 2021-02-25 | |||
| 2020-09-30 | 389.70K shares 10-Q · filed 2021-11-03 | 389.70M shares 10-Q · filed 2020-11-05 | 378.77K shares 10-Q · filed 2021-11-03 | 378.77M shares 10-Q · filed 2020-11-05 | ||
| 2020-03-31 | 361.14M shares 10-Q · filed 2021-04-29 | 360.24M shares derived: average of 2 quarters · filed 2021-04-29 | 357.16M shares derived: average of 3 quarters · filed 2021-04-29 | 350.58M shares derived: average of 4 quarters · filed 2021-04-29 | ||
| 2019-12-31 | 359.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 355.17M shares derived: average of 2 quarters · filed 2021-02-25 | 347.06M shares derived: average of 3 quarters · filed 2021-02-25 | 342.54M shares 10-K · filed 2021-02-25 | ||
| 2019-09-30 | 350.99M shares 10-Q · filed 2020-11-05 | 340.93M shares derived: average of 2 quarters · filed 2020-11-05 | 336.94M shares 10-Q · filed 2020-11-05 | 331.23M shares derived: average of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | 330.86M shares 10-Q · filed 2019-07-31 | 329.79M shares 10-Q · filed 2019-07-31 | 324.65M shares derived: average of 3 quarters · filed 2021-02-25 | 317.38M shares derived: average of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | 328.71M shares 10-Q · filed 2020-04-30 | 321.54M shares derived: average of 2 quarters · filed 2021-02-25 | 312.89M shares derived: average of 3 quarters · filed 2021-02-25 | 308.08M shares derived: average of 4 quarters · filed 2021-02-25 | ||
| 2018-12-31 | 314.37M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 304.98M shares derived: average of 2 quarters · filed 2021-02-25 | 301.21M shares derived: average of 3 quarters · filed 2021-02-25 | 297.24M shares 10-K · filed 2021-02-25 | ||
| 2018-09-30 | 295.60M shares 10-Q · filed 2019-11-05 | 294.63M shares derived: average of 2 quarters · filed 2019-11-05 | 291.53M shares 10-Q · filed 2019-11-05 | 286.34M shares derived: average of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | 293.66M shares 10-Q · filed 2019-07-31 | 289.46M shares 10-Q · filed 2019-07-31 | 283.26M shares derived: average of 3 quarters · filed 2020-02-25 | 280.15M shares derived: average of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | 285.21M shares 10-Q · filed 2019-05-01 | 278.06M shares derived: average of 2 quarters · filed 2020-02-25 | 275.64M shares derived: average of 3 quarters · filed 2020-02-25 | 274.41M shares derived: average of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | 270.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | 270.86M shares derived: average of 2 quarters · filed 2020-02-25 | 270.81M shares derived: average of 3 quarters · filed 2020-02-25 | 270.65M shares 10-K · filed 2020-02-25 | ||
| 2017-09-30 | 270.80M shares 10-Q · filed 2018-11-01 | 270.76M shares derived: average of 2 quarters · filed 2018-11-01 | 270.57M shares 10-Q · filed 2018-11-01 | 270.33M shares derived: average of 4 quarters · filed 2019-02-27 | ||
| 2017-06-30 | 270.73M shares 10-Q · filed 2018-08-01 | 270.44M shares 10-Q · filed 2018-08-01 | 270.18M shares derived: average of 3 quarters · filed 2019-02-27 | 254.92M shares derived: average of 4 quarters · filed 2019-02-27 | ||
| 2017-03-31 | 270.16M shares 10-Q · filed 2018-05-02 | 269.90M shares derived: average of 2 quarters · filed 2019-02-27 | 249.65M shares derived: average of 3 quarters · filed 2019-02-27 | 233.36M shares derived: average of 4 quarters · filed 2019-02-27 | ||
| 2016-12-31 | 269.64M shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | 239.40M shares derived: average of 2 quarters · filed 2019-02-27 | 221.09M shares derived: average of 3 quarters · filed 2019-02-27 | 211.87M shares 10-K · filed 2019-02-27 | ||
| 2016-09-30 | 209.15M shares 10-Q · filed 2017-11-01 | 196.81M shares derived: average of 2 quarters · filed 2017-11-01 | 192.62M shares 10-Q · filed 2017-11-01 | 190.24M shares derived: average of 4 quarters · filed 2018-02-27 | ||
| 2016-06-30 | 184.47M shares 10-Q · filed 2017-08-02 | 184.26M shares 10-Q · filed 2017-08-02 | 183.93M shares derived: average of 3 quarters · filed 2018-02-27 | 183.76M shares derived: average of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | 184.05M shares 10-Q · filed 2017-05-03 | 183.66M shares derived: average of 2 quarters · filed 2018-02-27 | 183.52M shares derived: average of 3 quarters · filed 2018-02-27 | 182.76M shares derived: average of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | 183.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | 183.26M shares derived: average of 2 quarters · filed 2018-02-27 | 182.33M shares derived: average of 3 quarters · filed 2018-02-27 | 180.65M shares 10-K · filed 2018-02-27 | ||
| 2015-09-30 | 183.25M shares 10-Q · filed 2016-11-03 | 181.85M shares derived: average of 2 quarters · filed 2016-11-03 | 179.78M shares 10-Q · filed 2016-11-03 | |||
| 2015-06-30 | 180.46M shares 10-Q · filed 2016-08-04 | 178.04M shares 10-Q · filed 2016-08-04 | ||||
| 2012-06-30 | 140.55M shares 10-Q · filed 2012-08-08 | 138.28M shares 10-Q · filed 2012-08-08 | ||||
| 2011-06-30 | 128.36M shares 10-Q · filed 2012-08-08 | 125.91M shares 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |